id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0126-0004,FDA,FDA-2014-E-0126,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-27T04:00:00Z,2014,5,2014-05-27T04:00:00Z,,2014-05-27T13:04:50Z,,0,0,090000648171558a
FDA-2014-E-0126-0003,FDA,FDA-2014-E-0126,Patent Extention Application from Morrison & Foerster LLP (on behalf of Novartic AG),Other,Application,2014-01-29T05:00:00Z,2014,1,2014-01-29T05:00:00Z,,2014-01-29T14:17:31Z,,0,0,090000648153193f
FDA-2014-E-0126-0002,FDA,FDA-2014-E-0126,Letter from U S Patent and Trademark Office,Other,Letter(s),2014-01-29T05:00:00Z,2014,1,2014-01-29T05:00:00Z,,2014-02-03T15:05:14Z,,0,0,0900006481531940
FDA-2014-E-0126-0001,FDA,FDA-2014-E-0126,Flucelvax - Patent Term Extension Application,Other,,2014-01-24T00:00:00Z,2014,1,,,2014-02-03T15:01:43Z,,0,1,0900006481524b3b